Is risk-stratified breast cancer screening economically efficient in Germany? by Arnold, Matthias et al.
This is a repository copy of Is risk-stratified breast cancer screening economically efficient 
in Germany?.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/146606/
Version: Published Version
Article:
Arnold, Matthias orcid.org/0000-0002-9736-7233, Pfeifer, Katharina and Quante, Anne S. 
(2019) Is risk-stratified breast cancer screening economically efficient in Germany? PLoS 
ONE. ISSN 1932-6203 
https://doi.org/10.1371/journal.pone.0217213
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
RESEARCH ARTICLE
Is risk-stratified breast cancer screening
economically efficient in Germany?
Matthias ArnoldID1,2,3, Katharina Pfeifer4, Anne S. Quante4
1 Centre for Health Economics, University of York, York, United Kingdom, 2 Munich Center of Health
Sciences, Ludwig-Maximilians-Universita¨t, Munich, Germany, 3 Institute of Health Economics and Health
Care Management, Helmholtz Zentrum Mu¨nchen – German Research Center for Environmental Health,
Neuherberg, Germany, 4 Frauenklinik, Klinikum Rechts der Isar, Technical University Munich (TUM),
Munich, Germany
* Matthias.arnold@york.ac.uk
Abstract
Objectives
Risk stratification has so far been evaluated under the assumption that women fully adhere
to screening recommendations. However, the participation in German cancer screening
programs remains low at 54%. The question arises whether risk-stratified screening is eco-
nomically efficient under the assumption that adherence is not perfect.
Method
We have adapted a micro-simulation Markov model to the German context. Annual, bien-
nial, and triennial routine screening are compared with five risk-adapted strategies using
thresholds of relative risk to stratify screening frequencies. We used three outcome vari-
ables (mortality reduction, quality-adjusted life years, and false-positive results) under the
assumption of full adherence vs. an adherence rate of 54%. Strategies are evaluated using
efficiency frontiers and probabilistic sensitivity analysis (PSA).
Results
The reduced adherence rate affects both performance and cost; incremental cost-effective-
ness ratios remain constant. The results of PSA show that risk-stratified screening strate-
gies are more efficient than biennial routine screening under certain conditions. At any
willingness-to-pay (WTP), there is a risk-stratified alternative with a higher likelihood of
being the best choice. However, without explicit decision criteria and WTP, risk-stratified
screening is not more efficient than biennial routine screening. Potential improvements in
the adherence rates have significant health gains and budgetary implications.
Conclusion
If the participation rate for mammographic screening is as low as in Germany, stratified
screening is not clearly more efficient than routine screening but dependent on the WTP. A
more promising design for future stratified strategies is the combination of risk stratification
mechanisms with interventions to improve the low adherence in selected high-risk groups.
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Introduction
When evaluating national mammography screening programs, it remains controversial
whether the benefits outperform the risks, such as false-positive screening results and unneces-
sary diagnostic procedures [1–4]. As trade-offs between risks and benefits may vary at the indi-
vidual level, an individualized program is very likely to represent a more effective approach
than population-wide criteria for screening. On one hand, it is desirable to avoid unnecessary
diagnostic procedures involving radiation in women who are unlikely to develop breast cancer.
On the other hand, there is a need to intensify diagnostic procedures for women at higher risk.
It is desirable to develop risk-stratified screening intervals based on the individual risk profile,
taking into account family history, breast density, and breast biopsies [5–8].
Recent studies have taken up the challenge of evaluating risk-stratified screening proposals
[5–10]. However, all evaluations were made under the assumption of full adherence [5–10]. In
our previous work [11], we were able demonstrate that the performance of screening programs
is sensitive to changes in the adherence assumption. Thus, assuming full adherence biases the
simulation results.
In Germany, women between 50 and 69 years are routinely invited to participate in mam-
mography screening every two years. The participation rate in the mammography screening
program is especially low at 54% [12] and does not reach the quality assurance goal of 70%
set within the European guidelines [13]. Therefore, it is essential to consider the actual par-
ticipation rate in an economic evaluation of risk-adapted screening strategies vs. routine
screening.
This economic evaluation evaluates both routine (with annual, biennial, or triennial inter-
vals) and proposals for stratified screening strategies (based on a narrow selection of risk fac-
tors found in the general population). We use a simulated German population in a Markov
decision model to compare these screening strategies under the assumption of full adherence
vs. an adherence rate of 54%.
Methods
We adapt a micro-simulation Markov model to represent the population and health system in
Germany. The model randomly selects different health states for women who are initially
healthy. Over the course of a lifetime, women may develop ductal carcinoma in situ (DCIS),
invasive breast cancer, or remain healthy and die from other causes. Women with DCIS may
or may not develop invasive cancer later on. Women with breast cancer may die from disease
or other causes. The probability of developing invasive breast cancer increases with age, high
density of the breast tissue (at 50 years of age, 48.3% of women have heterogeneously dense
and 6.9% have extremely dense tissue) [14], a positive history of breast cancer in a first-degree
relative (16.1% of women) [15], or previous biopsies (28.2% of women) [15]. Women can be
diagnosed with breast cancer in one of three stages: local, regional, or distant. The stage distri-
bution at diagnosis depends on the frequency with which mammography screening was per-
formed, age and breast density. The stage at time of diagnosis influences the annual survival
probability. Simulations run from a start age of 50 years (the age of the first screening invita-
tion for women in Germany [16]) until the end of life or 100 years for a total of 3,000,000
women, which produces stable results comparing within-strategy variance and between-strat-
egy variance [17]. An overview of the parameters used is given in Table 1 and described in
detail in the following. Additional descriptions regarding the adaptation from the original
model and the state transition diagram can be found in sectionModel description in the S1
Appendix.
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Incidence, survival, and mortality
We estimate invasive breast cancer and DCIS incidence from the German Center for Cancer
Registry Data (ZfKD) [18] and population estimates from the Federal Statistical Office using
age–period–cohort models (APC) [19], which allow calculation of age-specific incidence rates
while controlling for age, period, or cohort effects [20]. Details can be found in the sections
Invasive cancer incidence and DCIS incidence of the S1 Appendix. Breast cancer incidence is
modified by relative risk from three risk factors: family history of breast cancer [5, 21], per-
sonal history with biopsy [5, 21], and breast density [5, 15]. Relative risks are calculated as the
risk in developing breast cancer in the group carrying the risk factor over the risk of develop-
ing breast cancer in the risk not carrying the risk factors. These risk factors are chosen as
Table 1. Model input parameters.
Parameter Description Source
Population demographics
Background mortality Mortality in absence of breast cancer. Based on life tables and
cause of death statistics.
[20]
Natural history of breast cancer
Incidence of breast cancer in
absence of screening
Based on APC models to correct for age, period, and cohort
effects in national cancer registry data.
[18]
Stage distribution Stage distribution from detected cancer cases by age and
screening interval. Based on calculations from BCSC data.
[5, 15, 34]
Survival time Based on survival curves fromMunich Tumor Registry data. [23]
Breast cancer screening
Mammography adherence Assumed full adherence and reported participation rates in the
Mammography Evaluation reports.
[16]
Sensitivity of mammography Based on age and breast density. Mammographic vs. clinically
detected cancers are expressed in the stage distributions.
[5, 15, 34]
Specificity of mammography False-positive mammograms are calculated based on data from
the Mammography Evaluation reports.
[16]
Prevalence of breast density Based on the literature. [14, 22]
Risk levels for risk factors Relative risks of breast density, family history in first-degree
relative, and previous biopsies are based on the literature and
BCSC risk calculator.
[5, 15, 35]
Cost of screening and diagnostic
work-up
Based on the price catalog for ambulatory care (EBM). [36]
Health utility effects of screening
and diagnostic work-up
Based on EQ-5D tariff-based utility scores for mammography
screening, core needle biopsy, and vacuum biopsy. Biopsy is
weighted using probability of core needle and vacuum biopsy
reported in the Mammography Evaluation reports.
[16, 31,
37]
Breast cancer treatment
Treatment use Based on treatment pathways for triple negative, hormone
receptor-positive, and estrogen receptor-positive women
reported in an analysis from the German Consortium for
Hereditary Breast and Ovarian Cancer. Adapted for women of
moderate risk using guidelines, disease management programme
evaluation reports, and the literature.
[24, 25,
38–41]
Treatment effect Assumed to be included in the stage-dependent survival times. [23]
Cost of treatment Based on estimates based on an analysis from the German
Consortium for Hereditary Breast and Ovarian Cancer using the
price catalog for stationary care in a German cohort. Adapted for
women of moderate risk using guidelines and the literature.
[24, 42,
43]
Health utility effect of breast cancer
and treatment
Based on EQ-5D tariff-based estimates reported in the literature. [5, 27]
https://doi.org/10.1371/journal.pone.0217213.t001
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readily available representatives which are found in the general population. Each woman is
randomly assigned a risk combination at the start of the simulation. Breast density may change
every 5 years [22], which reflects empirically observed changes in breast tissue density [14].
Section Risk factors in the S1 Appendix describes the prevalence of risk factors in the popula-
tion, the changes in breast density, and the associated relative risks.
Survival in our simulation is dependent on the “Markov stage”: for healthy women or
women with DCIS, survival is calculated from the age-specific mortality rate from causes other
than breast cancer using data from the Federal Statistical Office [20]. The exact calculation is
described in section Background mortality in the S1 Appendix. For women with invasive breast
cancer at stages of local, regional, or distant cancers, mortality rates are determined by stage-
specific mortality rates. For each stage, we accordingly describe the cancer-specific survival or
mortality rates using data from the Munich Tumor Registry [23]. Details can be found in sec-
tion Breast cancer mortality in the S1 Appendix.
Cost and utility parameters
We chose the payer perspective of the statutory health insurances. All prices are standardized
to 2017 Euros, and the discount rate are set to 3% for cost and utility parameters. Prices are
based on the national price catalog (EBM), diagnosis-related groups (DRG), or published liter-
ature. For the mammography screening and associated additional procedures, we calculate the
costs as follows: mammography screening (½73.50), additional follow-up (½94.45), core needle
(½21.10), or vacuum biopsy (½39.79), section Diagnostic work up in the S1 Appendix describes
the probability used for each technology. Details of the EBM codes and prices can be found in
section Cost parameters of the S1 Appendix. Treatment pathways are based on estimates by
Muller, Danner [24] for German breast cancer (BRCA) susceptibility gene carriers and
adapted their treatment probabilities to reflect women over 50 years without BRCA gene
mutation. We use a classification of molecular subtypes, which are associated with distinct
treatment pathways in local, regional, or distant cancers. Based on Liedtke, Rody [25], we dis-
tinguish between triple negative (HER2/neu negative, estrogen receptor negative, and proges-
terone negative), hormone receptor negative and HER2/neu positive, and hormone receptor
positive with or without HER2/neu positive. We include surgical treatment (either mastec-
tomy or breast-conserving therapy), chemotherapy (plus Trastuzumab for HER2/neu), che-
motherapy-induced adverse events, endocrine therapy, and radiotherapy after surgery and
palliative care. All hospital-based costs are based on German DRG aggregates. Probabilities, lit-
erature sources, and sensitivity ranges can be found in section Cost parameters of the S1
Appendix.
For health utilities, we use EQ-5D estimates based on the time-trade-off tariff of Dolan [26].
Utility parameters for healthy women and breast cancer patients are based on EQ-5D estimates
from Lidgren, Wilking [27]. Losses in quality-adjusted life years (QALY) for screening and
diagnostic work up are based on literature. Section Utility parameters in the S1 Appendix
describes the literature used, the exact calculation, and the sensitivity ranges.
Screening strategies and adherence
Our risk stratification approach is to simulate screening intervals of 1 year, 2 years, or 3 years.
We use breast density-specific stage distribution for these intervals from the Breast Cancer
Surveillance Consortium (BCSC) [15]. We evaluate three routine screening strategies for
annual, biennial, and triennial intervals and a total of five risk-stratified strategies, where the
interval is based on the risk profile. These screening strategies were designed to represent
threshold based strategies with a degree of variation in the total number of screening events.
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This variation reflects different motives in decision makers (representing reduction or increase
in screening efforts on average). Based on the literature, we chose four different thresholds of
relative risks (RR) of 2, 1.5, 1, and 0.5 [28, 29] to create five combinations of high-, medium-,
and low-risk groups:
• Strategy RR 2–1 suggests annual screening for women with relative risk above 2.0, biennial
screening for women with relative risk between 1.0 and 2.0, and triennial screening for
women with relative risk below 1.0.
• Strategy RR 1–0.5 suggests annual screening for women with relative risk above 1.0, biennial
for women with relative risk between 0.5 and 1, and triennial for women with relative risk
below 0.5.
• Strategy RR 1.5–1 suggests annual screening for women with relative risk above 1.5, biennial
for women with relative risk between 1.5 and 1.0, and triennial for women with relative risk
below 1.0.
• Strategy RR 1.5–0.5 suggests annual screening for women with relative risk above 1.5, bien-
nial for women between 0.5 and 1.5, and a lower threshold of 0.5 for triennial screening.
• Strategy RR 2–0.5 suggests annual screening for women with a relative risk above 2.0, bien-
nial screening for women between 2.0 and 0.5, and triennial screening for women below 0.5.
Section Screening strategies in the S1 Appendix illustrates how these clusters transfer to risk
factor and age combinations. These five strategies are compared under two adherence assump-
tions: full adherence and the actual adherence rate in Germany of 54% [16]. Under the
assumption of the adherence rate of 54%, whether a woman attends screening or not is ran-
domly distributed. If a woman is diagnosed with breast cancer and has participated in screen-
ing, then her cancer stage is assigned based on the stage distribution of the respective
screening interval. If a woman has been diagnosed with breast cancer and has not participated
in screening, then her cancer stage is assigned based on the same stage distribution as women
who do not attend screening at all. Section Mammography screening and adherence in the S1
Appendix discusses the technical implementation.
Benefits and harms
We calculate incremental cost and incremental effect measures for three outcomes: breast can-
cer mortality reduction, QALY, and false-positive screening results. As a representation of
false-positive screening results, we tracked the number of biopsies only necessary to clarify
false-positive screening results, as they significantly affect quality of life [30–33]. Overdiagnosis
was implemented as harmful screening effect relative to the number of the screening events.
Uncertainty and probabilistic sensitivity analysis
We use univariate and probabilistic sensitivity analyses (PSA) to test parameter uncertainty on
the model robustness. The complete list of variables and the sensitivity ranges used are
described in section Distribution and ranges for sensitivity analysis of the S1 Appendix. For the
PSA, 500 runs with 3,000,000 trials were used, which were found to produce stable variance
with manageable computation time (of roughly 800 hours for the PSA with TreeAge Pro 2017
on an Intel i5 computer cluster with 32 cores). With cost-effectiveness acceptability curves
(CEAC), we compare PSA results over multiple outcomes as suggested by Stollenwerk, Lha-
chimi [44].
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Efficiency criteria
As suggested by the Institute for Quality and Efficiency in Health Care (IQWIG) [45], we do
not use a specific willingness-to-pay (WTP) threshold, but assess whether the strategies are
technically efficient alternatives compared with existing strategies. The efficiency frontier
describes the best combination of incremental cost and effect [46]. Efficient strategy would be
placed on the efficiency frontier, whereas inefficient proposals would be below the frontier
line.
For the PSA, we assess whether the CEAC lies strictly above the alternative strategy. In this
situation, the probability of being cost-effective for the first strategy is consistently higher than
its alternative. It would then be efficient to decide on the first strategy. In situations where the
CEACs intersect, the strategies change their rank if a certain WTP threshold is crossed. A
clearly defined WTP threshold is then necessary for the decision between two alternatives. In
the absence of such a clearly defined WTP, none of the alternatives is clearly efficient. We cal-
culate the expected value of perfect information (EVPI) to identify the monetary value of
uncertainty in the model.
Results
Table 2 presents the outcomes and costs of each screening strategy as increments compared
with a situation without screening under the assumption of full adherence vs. 54% adherence.
Fig 1 shows the efficiency frontiers representing outcomes for each strategy under the assump-
tion of full adherence vs. 54% adherence. The axis were standardized between the adherence
assumptions to represent the same ratio. The cost in Fig 1 represents additional spending for
each screening strategy. Each strategy produces mortality reduction and QALY, but also false-
positive screening results, which leads to unnecessary recall screening and in some cases
unnecessary biopsies.
Under the assumption of full adherence, routine biennial screening produces 14.46% mor-
tality reduction and 0.0386 incremental QALY (equivalent to 14 days in perfect health) at a
cost of ½427.8 per woman (Table 2). If adherence is 54%, routine biennial screening reduces
mortality by 8.81% and increases quality of life by 0.0233 at a cost of ½224.12. Mortality reduc-
tion is thus reduced by 39%, QALYs by 40%, and cost by 48%. When comparing this with the
other strategies, we find that the relative impact of non-adherence on performance and cost is
very homogeneous with only small variations. Adherence consistently affects performance and
cost, which is why incremental cost-effectiveness ratios (ICERs) remain consistent.
Overall, the performance of the screening strategies is reduced by approximately 40% but,
at the same time, about 48% costs are saved. This explains why the slope of the QALY effi-
ciency frontier (Fig 1) is less steep with 54% adherence than with full adherence. Thus, the
investment in more intensive screening differs under the assumption of full vs. 54% adherence.
As an example: changing from triennial routine screening to annual screening costs additional
½505.66 and returns additional 0.0116 QALYs if full adherence is assumed, which is a ratio
½43,591 per QALY. If adherence is 54% though, the same investment costs ½273.61 for 0.0057
QALY, which is a ratio of ½48,001 per QALY. Adherence thus affects the returns on the screen-
ing investment.
The subgroup analysis in Table 3 shows the performance of the risk strategies within the
risk groups. Small variations between risk groups in different strategies but with identical
screening recommendations are to be expected due to the randomization of the micro-simula-
tion (for example the difference in results between the annual risk group in RR2-1 and RR2-
0.5). As expected, the greater the relative risk threshold, the better is the performance for
annual screening in terms of mortality reduction and QALY in the high-risk group. If the
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high-risk group is defined by a relative risk above 2.0 and consequently screened annually, the
mortality reduction is 91.2% in RR2-1 (or 91.9% in RR2-0.5). If the high-risk group is assigned
to women with relative risk above 1.5, the mortality reduction is 41.3% in RR1.5–1.0 or (41.4%
in RR1.5–0.5). Similarly also for the low-risk group, the mortality reduction depends on the
chosen threshold. If the low-risk group is defined by a relative risk below 0.5 and screened
Table 2. Outcomes and costs as increments per strategy vs. no screening, mean (confidence interval) per woman.
Adherence Strategies Mortality reduction (in %) Incremental QALY Biopsies after false-positive screening Incremental cost (2017 Euro)
Full Adherence Routine 3-year 12.22 (12.26–12.19) 0.033 (0.033,0.033) 0.037 (0.036,0.037) 305.18 (305.15,305.22)
Routine 2-year 14.46 (14.5–14.42) 0.039 (0.039,0.039) 0.050 (0.050,0.051) 427.8 (427.76,427.83)
Routine 1-year 16.92 (16.96–16.87) 0.044 (0.044,0.044) 0.096 (0.095,0.096) 810.84 (810.85,810.83)
RR 2–1 14.26 (14.3–14.22) 0.038 (0.038,0.038) 0.048 (0.048,0.048) 404.48 (404.44,404.53)
RR 1–0.5 16.46 (16.51,16.42) 0.043 (0.043,0.043) 0.081 (0.080,0.081) 684.76 (684.75,684.78)
RR 2–05 14.64 (14.68,14.6) 0.039 (0.039,0.039) 0.052 (0.051,0.052) 438.52 (438.48,438.56)
RR 1.5–1.0 14.96 (15,14.92) 0.040 (0.040,0.040) 0.056 (0.056,0.056) 474.15 (474.11,474.2)
RR 1.5–0.5 15.34 (15.39,15.3) 0.041 (0.041,0.041) 0.060 (0.060,0.060) 508.42 (508.38,508.46)
54% Adherence Routine 3-year 7.68 (7.71,7.66) 0.020 (0.020,0.020) 0.022 (0.022,0.022) 157.14 (157.12,157.16)
Routine 2-year 8.81 (8.83,8.78) 0.023 (0.023,0.023) 0.030 (0.029,0.030) 224.12 (224.1,224.14)
Routine 1-year 9.99 (10.02,9.97) 0.026 (0.026,0.026) 0.054 (0.054,0.054) 430.75 (430.75,430.74)
RR 2–1 8.63 (8.66,8.61) 0.023 (0.023,0.023) 0.028 (0.028,0.028) 211.13 (211.1,211.15)
RR 1–0.5 9.7 (9.73,9.68) 0.025 (0.025,0.025) 0.046 (0.045,0.046) 362.46 (362.45,362.47)
RR 2–05 8.82 (8.85,8.8) 0.023 (0.023,0.023) 0.030 (0.030,0.030) 229.97 (229.95,229.99)
RR 1.5–1.0 8.95 (8.98,8.93) 0.024 (0.024,0.024) 0.032 (0.032,0.033) 248.55 (248.53,248.58)
RR 1.5–0.5 9.14 (9.17,9.12) 0.024 (0.024,0.024) 0.035 (0.034,0.035) 267.54 (267.51,267.56)
https://doi.org/10.1371/journal.pone.0217213.t002
Fig 1. Cost-effectiveness efficiency frontiers.
https://doi.org/10.1371/journal.pone.0217213.g001
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triennially, then the mortality reduction is 5.1% with RR 2–0.5 and RR1.5–0.5 (or 5.6% in
RR1-0.5). This reflects the lower incidence in this low-risk group, which is 6.9% lifetime
incidence.
Raising adherence rates in specific risk groups offers promising performance gains. Divid-
ing the total performance gain through the adherence increase gives the average gain for each
percent increase. Given biennial routine screening, each increase of 1% in the participation
Table 3. Subgroup analysis, performance in clusters.
Strategy Screening
cluster
Population in
cluster (%)
Incidence in
cluster (%)
Mortality
reduction with
full adherence
Mortality
reduction with
54% adherence
Loss due to low
adherence (%)
QALY in full
adherence
QALY in 54%
adherence
Loss due to low
adherence (%)
Routine
3-year
Annual 0.0
Biennial 0.0
Triennial 100 12.3 –11.2 (–11.4,–11) –7.1 (–7.2,–6.9) –37 0.027
(0.027,0.028)
0.017
(0.017,0.017)
–37
Routine
2-year
Annual 0.0
Biennial 100 12.3 –14.3 (–14.5,–14) –8.7 (–8.9,–8.5) –39 0.037
(0.036,0.037)
0.022
(0.022,0.023)
–41
Triennial 0.0
Routine
1-year
Annual 100 12.3 –17.4 (–17.6,–
17.1)
–10.3 (–10.5,–
10.1)
–41 0.045
(0.045,0.046)
0.027
(0.026,0.027)
–40
Biennial 0.0
Triennial 0.0
RR 2–1 Annual 1.6 42.0 –91.2 (–95.6,–
86.8)
–50.9 (–54.2,–
47.6)
–44 0.336
(0.322,0.35)
0.191
(0.18,0.201)
–43
Biennial 50.6 15.3 –18.7 (–19.1,–
18.4)
–11.3 (–11.6,–11) –40 0.05
(0.049,0.051)
0.03
(0.03,0.031)
–40
Triennial 47.7 8.6 –7.7 (–7.9,–7.4) –4.8 (–5,–4.7) –38 0.017
(0.016,0.017)
0.01
(0.01,0.011)
–41
RR 1–0.5 Annual 46.1 16.7 –25.7 (–26.1,–
25.2)
–14.9 (–15.3,–
14.6)
–42 0.071
(0.07,0.072)
0.041
(0.041,0.042)
–42
Biennial 48.5 9.1 –9.8 (–10.1,–9.5) –6 (–6.2,–5.8) –39 0.022
(0.022,0.023)
0.013
(0.013,0.014)
–41
Triennial 5.4 6.7 –5.6 (–6.2,–5) –3.5 (–4,–3) –37 0.012
(0.011,0.014)
0.008
(0.007,0.009)
–33
RR 2–0.5 Annual 1.6 42.0 –91.9 (–96.3,–
87.5)
–51.3 (–54.6,–48) –44 0.34
(0.326,0.354)
0.193
(0.182,0.204)
–43
Biennial 90.0 12.5 –14.6 (–14.8,–
14.3)
–8.8 (–9,–8.7) –40 0.037
(0.037,0.038)
0.023
(0.022,0.023)
–38
Triennial 8.4 6.9 –5.1 (–5.5,–4.6) –3.1 (–3.5,–2.7) –39 0.011
(0.01,0.012)
0.007
(0.006,0.008)
–36
RR 1.5–
1.0
Annual 11.9 24.1 –41.3 (–42.4,–
40.2)
–23.8 (–24.7,–23) –42 0.126
(0.123,0.129)
0.073
(0.07,0.075)
–42
Biennial 42.2 13.7 –16.4 (–16.8,–
16.1)
–9.8 (–10.1,–9.5) –40 0.043
(0.042,0.044)
0.026
(0.025,0.026)
–40
Triennial 45.9 8.5 –7.6 (–7.9,–7.4) –4.8 (–5,–4.6) –37 0.017
(0.016,0.017)
0.01
(0.01,0.011)
–41
RR 1.5–
0.5
Annual 11.9 24.1 –41.4 (–42.5,–
40.3)
–23.9 (–24.7,–23) –42 0.127
(0.124,0.13)
0.073
(0.071,0.075)
–43
Biennial 79.7 11.4 –13.1 (–13.3,–
12.8)
–7.9 (–8.1,–7.7) –40 0.032
(0.032,0.033)
0.019
(0.019,0.02)
–41
Triennial 8.4 6.9 –5.1 (–5.5,–4.6) –3.1 (–3.5,–2.7) –39 0.011
(0.01,0.012)
0.007
(0.006,0.008)
–36
https://doi.org/10.1371/journal.pone.0217213.t003
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rate results in an increase of 0.85% in mortality reduction and QALY increase of 0.90% on
average. However, when increasing the adherence by 1% for women at high risk, e.g., a relative
risk higher than 2.0 (1.6% of the population), then this results in an increase in mortality
reduction of 0.96% and QALY of 0.93% for this risk group. If the high-risk group is defined by
a relative risk of 1.5% and higher, then an increase in adherence by 1% would increase mortal-
ity reduction by 0.91% and QALY by 0.91%.
From the CEAC Fig 2, we learn that strategy selection depends on the health outcome, the
corresponding WTP, and the adherence assumption. If mortality reduction is most important
for decision makers, the recommendation should be as follows: at least ½54,000 is required to
justify the most basic screening strategy, which is routine triennial. This is the case for both
full adherence and 54% adherence assumptions, with only small differences. If WTP is over
½54,000, the adherence assumption matters. For full adherence, triennial routine screening is
the best strategy until WTP reaches ½129,000; then RR 2–1 is the best choice for WTP up to
½216,000. If adherence is at 54%, however, RR 2–1 intersects with biennial routine screening at
½243,000. As RR 2–1 is not always better than routine biennial, it is not clearly economically
more efficient. Although there are stratified strategies with higher cost-effectiveness for parts
of the WTP scale, there is no strategy clearly dominating biennial routine screening.
If quality of life is the most important criteria, RR 2–1 qualifies as an economically efficient
alternative to biennial routine screening. At least ½8,000 is required for triennial screening to
have a higher probability of being acceptable than no screening. Triennial routine screening is
the best alternative for WTP up to ½19,000. For higher WTP, the adherence assumption then
matters. If full adherence is assumed, RR 2–1 is the best alternative up to WTP of ½34,000. For
54% adherence, RR 2–1 remains the most cost-effective strategy until WTP reaches ½36,000.
In contrast to decisions based on mortality reduction, however, RR 2–1 never intersects with
biennial routine screening. For decisions based on quality of life, RR 2–1 is thus more efficient
than biennial routine screening.
Looking at the overall uncertainty (the frontier line along the highest CEACs), Fig 2 shows
that the probability of having made the right decision is lower with 54% adherence than with
full adherence. From the univariate sensitivity analysis in Fig I of the S1 Appendix, we know
that the uncertainty is driven by the cost of mammography, the discount rate, the adherence
rate, and the incidence of invasive cancers. However, the two most important factors are
potentially overdiagnosed cases and QALY losses from screening.
The difference in EVPI between the full adherence and 54% adherence scenarios is ½68 per
women (assuming an arbitrary WTP of ½30,000 per QALY in absence of national estimates).
The uncertainty about the adherence assumption thus has substantial monetary implications.
Discussion
Low participation rates in screening programs are common in many European countries.
However, in economic evaluations, low adherence has not received much attention so far. For
the economic evaluation of screening strategies, non-adherence affects both cost and effects
simultaneously, and thus does not necessarily affect decisions based on the ratio of the incre-
mental cost and effect differences. Thus, a plausible simplification so far has been to disregard
low adherence in the economic evaluation. However, we were able to demonstrate in an earlier
study that this argument is no longer valid [11]. The results showed that economic recommen-
dations depend on the behavioral assumption underlying non-adherence and the adherence
level. Therefore, the aim in the present study was to evaluate economically five different risk-
adapted screening strategies and routine screening under the assumption of full adherence vs.
the actual adherence rate of 54%.
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Our results show that the actual participation rate of 54% substantially reduces the perfor-
mance of the biennial routine screening program, but also saves 52% of the program cost. At
54% adherence, screening in Germany currently results in a mortality reduction of 9% instead
of 16%, which would be possible if full adherence was achieved.
Our analysis shows that risk-stratified screening programs can be more efficient, but the
decision is dependent on the decision criteria, i.e., whether mortality reduction or QALY is
more important, how much one is willing to pay for these health outcomes, and the adherence
assumption. If quality of life is the decision criteria, RR 2–1 is a more efficient alternative to
routine biennial screening. Depending on the WTP, though, other stratified screening pro-
grams may be preferable alternatives. However, if mortality reduction is more important than
quality of life and adherence is 54%, RR 2–1 is not consistently more efficient. In this case,
there is no clearly better alternative for all WTP thresholds. The efficiency of risk-stratified
screening thus depends on the importance of the decision criteria, the WTP for the criteria,
and the actual adherence assumptions.
In addition, the return on investments in screening strategies is affected by adherence.
With 54% adherence, the return on investing money in more intensified screening is smaller
than expected at full adherence. Every percentage adherence gain is estimated to increase mor-
tality reduction by 0.80% and QALY by 0.85%. Although increasing adherence in the general
population could be very difficult and costly, a narrow focus on a selected high-risk population
could however produce bigger performance gains. Increasing adherence in women with high
relative risk produces even greater increases in mortality reduction and QALY. The value of
information analysis demonstrated that adherence gains have substantial monetary
implications.
Fig 2. Cost-effectiveness acceptability curves.
https://doi.org/10.1371/journal.pone.0217213.g002
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Our analysis has some limitations. First, our model is based on screening performance as
observed with analog screen-film mammography. We used this screening technology because
the literature used is based on screen-film mammography. This technology is still widely used,
but is being replaced by full-field digital mammography. Digital mammography has the advan-
tage of being more accurate in terms of specificity and sensitivity, and thus may improve
screening performance [47], especially in women with dense breast tissue [48]. However, the
performance increase in women over 50 years is small [49], and there is no evidence that
screening adherence differs between analog or digital screening. Second, in the mathematical
implementation of the adherence behavior, we relied on published data from the German
mammography screening program. In their evaluation reports, they provide detailed informa-
tion about the recent numbers of invited women and participation rates. However, they do not
provide an analysis of the risk within participating and non-participating women. In the
absence of this information, we used meta-analyses and systematic reviews describing the exis-
tence of a positive association between risk and adherence behavior [50–53] and another sys-
tematic review describing the extent of this relationship [53]. However, these studies are not
based on the German population. There is evidence suggesting that adherence is also influ-
enced by risk in Germany [54]. Third, this model was originally designed and evaluated in the
context of the U.S.A. Our adaptation to the German context utilizes all information and
sources that we were aware of. However, there are some elements that could not be adapted.
These elements are explicitly the relative risks of developing breast cancer, based on the three
risk factors, breast density, family history in a first-degree relative, and previous biopsies, and
the cancer stage-specific performance of mammography screening. These three risk factors
describe a spectrum of relative risk between 0.33 and 2.88 and thus represent the full risk spec-
trum associated with women in the general population who are eligible for the mammography
screening program in Germany.
Fourth, our model does not incorporate a natural history component of breast cancer.
Instead, we rely on the stage-specific detection rates, which implicitly include the natural pro-
gression, but do not allow distinction between detected and undetected cancers. Therefore,
our model underestimates the effect of mammographic screening, as we only incorporate its
effect via the stage shift at diagnosis, but not at earlier diagnosis.
Conclusion
In this economic evaluation, we compared the cost-effectiveness of risk-stratified screening
strategies under the assumption of full adherence and the situation in Germany with a 54%
adherence rate. By comparing these two scenarios from the perspective of a decision maker,
we aimed to discover whether risk-stratified screening is an economically efficient alternative
to routine screening in Germany.
We have shown that a decision for or against risk-stratified screening requires explicit deci-
sion criteria. The strategies that maximize mortality reduction do not necessarily also maxi-
mize quality of life. In addition, decisions based on perfect assumptions are not the same as
decisions based on real-world data. Risk-stratified screening is economically efficient only if
adherence is perfect. If adherence is as low as in Germany, stratified screening is not clearly
better than routine screening, but dependent on the decision criteria and the actual WTP.
A more promising design for new screening strategies thus consists of combinations of risk
stratification mechanisms with interventions to address and improve the low adherence in
selected high-risk groups.
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